Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Self-Injection at Home a Boon to Patients with Migraines
April 7, 2008
- JAPhMed Seminar Covers Wide Range of Topics
March 31, 2008
- Eli Lilly Japan Aims at \100 Billion Sales in 2008: President Crenshaw
March 31, 2008
- JAPhMed to Take 1st Exam for Pharmaceutical Medicine
March 31, 2008
- Korosho to Start Chronic Kidney Disease Research Project in October
March 31, 2008
- JCROA to Introduce Monitor Certification System
March 31, 2008
- 174 More Hospitals to Be Designated as DPC Hospitals
March 31, 2008
- Usefulness of Tavocept Confirmed: ASKA
March 31, 2008
- Fees for 5 Standard Chemotherapy Regimens to Be Raised in April
March 31, 2008
- Treatment Architecture Japan 2007 Published by Synix
March 31, 2008
- REGULATORY NEWS IN BRIEF
March 31, 2008
- GENERICS NEWS IN BRIEF
March 31, 2008
- OPINION／The Scuttlebutt on Pharma Takeovers
March 31, 2008
- 78 Generics of Amlodipine from 38 Companies Approved
March 31, 2008
- PET Facility Goes Bankrupt
March 31, 2008
- 16 APIs See Approval of 1st Generics
March 31, 2008
- 2 Former Company Employees Assigned to PMDA's Review Division within 2 Years of Employment
March 31, 2008
- BUSINESS NEWS IN BRIEF
March 31, 2008
- Reduction in Yakkasa Essential for Drug Pricing System Reform Proposed by Industry: FPMAJ President
March 31, 2008
- 2nd Dialogue Held by Korosho and FJPWA
March 31, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…